{
  "scenario_id": "biotech_gene_therapy_ethics_2025",
  "context": "Biotechnology company developing gene therapy treatments for rare genetic disorders, facing ethical decision on proceeding with clinical trials involving germline modifications",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "Board of Directors",
      "Ethics Committee"
    ],
    "influencers": [
      "Regulatory Affairs",
      "Legal Counsel",
      "Patient Advocacy Groups",
      "Scientific Advisory Board"
    ]
  },
  "request": {
    "amount": "$35 million",
    "purpose": "Phase 1/2 clinical trials for gene therapy targeting cystic fibrosis",
    "urgency": "high",
    "justification": "Potential to provide lifelong cure for genetic disease affecting 30,000 Americans"
  },
  "decision_process": [
    {
      "stage": "ethical_review",
      "duration": "4 months",
      "activities": [
        "Ethics committee consultation",
        "Patient advocacy group meetings",
        "Regulatory landscape analysis"
      ],
      "outcome": "Conditional approval with enhanced safety monitoring requirements"
    },
    {
      "stage": "scientific_validation",
      "duration": "3 months",
      "activities": [
        "Preclinical data review",
        "Independent safety assessment",
        "Peer review publication"
      ],
      "outcome": "Strong scientific rationale validated with acceptable risk profile"
    },
    {
      "stage": "regulatory_engagement",
      "duration": "2 months",
      "activities": [
        "FDA pre-IND meeting",
        "EMA scientific advice",
        "Regulatory pathway clarification"
      ],
      "outcome": "Clear regulatory pathway established with accelerated approval potential"
    }
  ],
  "business_impact": {
    "expected_revenue": "$750 million (10-year projection)",
    "projected_market_share": "25% of genetic therapy market",
    "risk_factors": [
      "Clinical trial setbacks",
      "Regulatory rejection",
      "Ethical controversies",
      "Manufacturing challenges"
    ]
  }
}
